Simlandi™

INN: adalimumab

Approved for use in:

Crohn’s Disease (moderate-severe)
Ulcerative Colitis (moderate-severe)

Type/Class

Biosimilar

Delivery Route

Subcutaneous Injection

Health Canada Approval

2022

Storage

Refrigerate between 2 and 8°C, do not freeze, keep in original carton to protect from light, may be stored at room temperature (up to 25°C) for a single period of up to 30 days.

Use in Older Adults (65+)

May be used, please consult your doctor.

Pregnancy Indication

No pattern of major birth defects has been observed; infants may be at increased risk for infection.

Breastfeeding Indication

Low exposure levels due to large molecule size and degradation by GI tract.

Pediatric Indication

Not used for pediatric IBD.

Learn More

View the Simlandi™ product monograph.